Table 2.

Visual acuity and visual field at initial visit

	Steroid therapy started ≤2 weeks of onset	Steroid therapy started >2 weeks of onset	All eyes
Visual acuity	(n=263 eyes)	(n=101 eyes)	(n=364 eyes)
20/15–20/20	91 (35%)	27 (27%)	118 (32%)
20–25–20/30	48 (18%)	20 (20%)	68 (19%)
20/40–20/60	53 (20%)	27 (27%)	80 (22%)
20/70–20/100	26 (10%)	8 (8%)	34 (9%)
20/200–20/400	12 (5%)	4 (4%)	16 (4%)
Counting fingers or worse	33 (13%)	15 (15%)	48 (13%)
Visual field defect	(n=262 eyes)#	(n=101 eyes)	(n=363 eyes) #
Minimal	11 (4%)	7 (7%)	18 (5%)
Mild	66 (25%)	23 (23%)	89 (25%)
Moderate	62 (24%)	21 (21%)	83 (23%)
Marked	86 (33%)	35 (35%)	121 (33%)
Severe	37 (14%)	15 (15%)	52 (14%)

^#Missing visual field defect data in one eye No significant difference in visual acuity (p=0.45) and visual field defect (p=0.96) between those that started steroid within 2 weeks of onset and those that started greater than 2 weeks of onset